Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time. Mumbai-headquartered Lupin is firming up plans to......
The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India. Pharma major Lupin has divested its entire stake in its Japanese subsidiary,......
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally. Kyowa Pharmaceutical Industry, drug major Lupin's Japanese subsidiary, has......
Talks to expand India-Japan trade pact remain a work in progress, even as trade deficit with Japan widens, says Nayanima Basu.The much-awaited review of the India-Japan comprehensive economic......
Kamal Sharma isn't fond of networking dos - he'd rather have roti-sabzi with office colleagues. He prefers to work 16 hours a day, away from the limelight; uses his free time to teach IIT students......